|
LAS VEGAS --Dr. Ercole Cavalieri and Dr. Eleanor Rogen of the University of Nebraska Medical Center, Eppley Institute for Research in Cancer, located in Omaha, Nebraska, have identified the triggering mechanism by which breast and prostate cancer cells begin. Preventium™ http://www.preventium.org is a recently developed dietary supplement that promises to reduce people's risk for breast and prostate cancer. Ercole Cavalieri, D.Sc. and research collaborator Eleanor Rogen, Ph.D. say: "We have found the first step that starts a cell down the road to becoming a cancer cell. By blocking this first step from happening, we feel we can stop the development of breast and prostate cancer."
The researchers have discovered that certain estrogen derivates (metabolites) can react with deoxyribonucleic acid (DNA) to cause damage that may initiate the start of breast and prostate cancer. Estrogen can initiate cancer when natural protective mechanisms do not function properly in the body, which then allows estrogen metabolites to react with DNA. Since both men and women have naturally occurring estrogen, the triggering mechanism for breast and prostate cancer is identical. This research has been funded in part by nearly $40 million in direct funding from the National Cancer Institute and the U.S. Defense Department.
Drs. Cavalieri and Rogan are the first cancer researchers to study the effects of Resveratrol on this process. New research establishes, that to be effective, additional compounds must be added for optimal effect. The combination of naturally occurring preventative agents Resveratrol, N-Acetyl-L-Cysteine (NAC), Lipoic Acid and Melatonin greatly enhances the body's natural protection mechanisms which, in turn, decrease the triggering mechanism involved in the formation of breast and prostate cancer cells. These compounds are available in a recently developed dietary supplement called Preventium™.
Preventium, LLC, a Las Vegas, Nevada company, was formed in association with our research scientists to assist women and men in achieving and maintaining healthy, normal levels of estrogen metabolites through the use of Preventium™. Supporting documentation about the science and research is available upon request.
The above scientist and science have been published in the following publications:
International Journal of Cancer
Cancer Prevention Research
Breast Cancer Basic and Clinical Research
Prostate
Journal of Steriod Biochemistry and Molecular Biology
Contacts
Preventium, LLC
John Raffanti, 702-809-9447
johnraffanti@preventium.org